Figure 4.High expression of CD163 is associated with worse prognosis of nasopharyngeal carcinoma. Survival was estimated by the Kaplan-Meier method and compared with log-rank tests. (A) The CD163 high group exhibited significantly lower overall survival than the CD163 low group (log-rank p-value = 0.004). (B) The CD163 high group exhibited significantly lower progression-free survival than the CD163 low group (log-rank p-value = 0.049). (C, D) The CD163 high group exhibited lower local-regional failure-free survival and distant metastasis-free survival than the CD163 low group, but the differences are not statistically significant (log-rank p-values>0.05).
